课题基金 / 基金详情

项目摘要

项目成果

Lee Marshall Nadler的其他基金

相似基金

相关文献

中文摘要
翻译
哈佛催化剂已经超越了历史,企业和文化长期强加的界限 哈佛及其17个附属学术医疗保健中心(AHC)的独立性, 研究人员一起合作并组成团队进行临床和转化(CT)研究。 今天,教育、资源和服务是由联合国共同规划、执行、广泛共享和评估的。 共同的目标是提高质量,速度,安全性,效率和成本在整个频谱的 CT研究持续的CTSA认可,加上有机会成为 联盟将使哈佛催化剂实现其愿景和战略计划。首先我们要召集 来自我们11所学校和17个AHC的调查人员,以确定和优先考虑最重要的机会, CT研究我们将帮助他们相互联系,形成跨学科的团队, 为他们提供机会,激励,并获得优秀的教育和资源, 重视创新、协作和团队科学的环境。第二,我们将与学校合作, 和AHC建立和发展一个快速有效地将发现转化为 改善人类健康。简单地说,哈佛催化剂努力成为召集者,连接器和催化剂 加快和提高CT研究的质量。为此,我们构建了我们的学术家园, 创建教育、培训和职业发展的综合途径,并提供 创新的资源和服务,以解决已查明的差距和调查员的需求。五年内,我们 成果将包括:1)在所有CT中建立一个持续、可持续、强大的未来团队领导者管道 2)SHRINE-CT的实施与监管障碍的解决相结合, 研究者能够快速识别、联系和招募特定患者参加跨机构的临床试验, 3)建立一个专家小组,减少 参与和进入人体实验,从而发展和多样化的社区, 进行CT研究的研究者; 4)为所有CT研究者提供访问 他们需要的资源,以进行人类临床研究,无论他们的工作是最好的;和5)系统 调查创新方法,以激励、组建和培养团队来创造新的预防措施, 生物标记物和治疗剂。这些成果将继续推动CT研究的变革, 哈佛的目标是催化一个“一个哈佛”的社区和文化,致力于改善健康。 相关性(参见说明): 哈佛临床和转化科学中心支持一个学术之家, 在哈佛医学院及其合作机构的综合研究和培训环境, 以改善人类健康。它提供和/或创建对资源和服务的访问,以支持所有 跨临床和转化研究的全方位临床研究的步骤,并促进 翻译研究人员的培训和职业发展。
英文摘要
Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow investigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a "One Harvard" community and culture committed to improving health. RELEVANCE (See instructions): The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Harvard Clinical and Translational Science Center
  • 批准号:
    10622007
  • 项目类别:
  • 资助金额:
    $1090.42万
  • 财政年份:
    2023
  • 负责人:
    Lee Marshall Nadler
  • 依托单位:
The Harvard Clinical and Translational Science Center
  • 批准号:
    10398988
  • 项目类别:
  • 资助金额:
    $1286.73万
  • 财政年份:
    2018
  • 负责人:
    Lee Marshall Nadler
  • 依托单位:
SMART IRB, A NATIONAL SINGLE IRB RELIANCE PLATFORM TO SUPPORT MULTI-SITE HUMAN RESEARCH STUDIES
  • 批准号:
    10370538
  • 项目类别:
  • 资助金额:
    $183.68万
  • 财政年份:
    2018
  • 负责人:
    Lee Marshall Nadler
  • 依托单位:
The Harvard Clinical and Translational Science Center
  • 批准号:
    10457151
  • 项目类别:
  • 资助金额:
    $19.18万
  • 财政年份:
    2018
  • 负责人:
    Lee Marshall Nadler
  • 依托单位:
海外基金